Phase I and II trials of novel anti-cancer agents : Endpoints, efficacy and existentialism : The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998EISENHAUER, E. A.Annals of oncology. 1998, Vol 9, Num 10, pp 1047-1052, issn 0923-7534Article

High-dose chemotherapy: Is it standard management for any common solid tumor?MACNEIL, M; EISENHAUER, E. A.Annals of oncology. 1999, Vol 10, Num 10, pp 1145-1161, issn 0923-7534Article

Current perspectives on camptothecins in cancer treatmentDANCEY, J; EISENHAUER, E. A.British journal of cancer. 1996, Vol 74, Num 3, pp 327-338, issn 0007-0920Article

RECIST revisited : A review of validation studies on tumour assessmentTHERASSE, P; EISENHAUER, E. A; VERWEIJ, J et al.European journal of cancer (1990). 2006, Vol 42, Num 8, pp 1031-1039, issn 0959-8049, 9 p.Article

Phase I trial design : Are new methodologies being put into practice ?DENT, S. F; EISENHAUER, E. A.Annals of oncology. 1996, Vol 7, Num 6, pp 561-566, issn 0923-7534Article

Response evaluation : beyond RECISTEISENHAUER, E. A.Annals of oncology. 2007, Vol 18, issn 0923-7534, ix29-ix32, SUP9Conference Paper

The taxoids : Comparative clinical pharmacology and therapeutic potentialEISENHAUER, E. A; VERMORKEN, J. B.Drugs (Basel). 1998, Vol 55, Num 1, pp 5-30, issn 0012-6667Article

Update in methodology and conduct of cancer clinical trialsTHERASSE, P; EISENHAUER, E. A; BUYSE, M et al.European journal of cancer (1990). 2006, Vol 42, Num 10, pp 1322-1330, issn 0959-8049, 9 p.Article

Novel endpoints and design of early clinical trialsPARULEKAR, W. R; EISENHAUER, E. A.Annals of oncology. 2002, Vol 13, pp 139-143, issn 0923-7534, 5 p., SUP4Conference Paper

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin―Topotecan and Carboplatin―Paclitaxel vs Carboplatin―PaclitaxelHOSKINS, P; VERGOTE, I; GHATAGE, P et al.Journal of the National Cancer Institute. 2010, Vol 102, Num 20, pp 1547-1556, issn 0027-8874, 10 p.Article

Anticancer agents targeting signaling molecules and cancer cell environment : Challenges for drug development?GELMON, K. A; EISENHAUER, E. A; HARRIS, A. L et al.Journal of the National Cancer Institute. 1999, Vol 91, Num 15, pp 1281-1287, issn 0027-8874Article

Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcomaBRAMWELL, V. H. C; EISENHAUER, E. A; BLACKSTEIN, M et al.Annals of oncology. 1995, Vol 6, Num 8, pp 847-849, issn 0923-7534Article

Toxicity of oral N-methylformamide in three phase II trials: a report from the national cancer institute of Canada clinical trials groupEISENHAUER, E. A; WEINERMAN, B. H; KERR, I et al.Cancer treatment reports. 1986, Vol 70, Num 7, pp 881-883, issn 0361-5960Article

Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group StudyEISENHAUER, E. A; EVANS, W. K; RAGHAVAN, D et al.Cancer treatment reports. 1986, Vol 70, Num 8, pp 1029-1030, issn 0361-5960Article

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)KOLLMANNSBERGER, C; HIRTE, H; OZA, A. M et al.Annals of oncology. 2012, Vol 23, Num 1, pp 238-244, issn 0923-7534, 7 p.Article

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative studyWEBERPALS, J. I; TU, D; SQUIRE, J. A et al.Annals of oncology. 2011, Vol 22, Num 11, pp 2403-2410, issn 0923-7534, 8 p.Article

Phase II study of subcutaneous rHU-interleukin-2 and rHu-interferon α-2a in previously treated patients with multiple myelomaBELCH, A. R; EISENHAUER, E. A; MULDAL, A et al.Annals of oncology. 1995, Vol 6, Num 7, pp 721-723, issn 0923-7534Article

Clinical toxicities encountered with paclitaxel (TAXOL®)ROWINSKY, E. K; EISENHAUER, E. A; CHAUDHRY, V et al.Seminars in oncology. 1993, Vol 20, Num 4, pp 1-15, issn 0093-7754, SUP3Conference Paper

Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer : a national cancer institute of Canada clinical trials group studySTEWART, D. J; EISENHAUER, E. A; SKILLINGS, J et al.Annals of oncology. 1992, Vol 3, Num 3, pp 201-204, issn 0923-7534Article

Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma: a study of the national cancer institute of Canada clinical trials groupEISENHAUER, E. A; SILVER, H. K; VENNER, P. M et al.British journal of cancer. 1987, Vol 55, Num 5, pp 541-542, issn 0007-0920Article

Phase II study of Iv menogaril in patients with malignant melanoma: a national cancer institute of Canada clinical trials group studyMCCULLOCH, P. B; EISENHAUER, E. A; SHIBATA, H. R et al.Cancer treatment reports. 1987, Vol 71, Num 7-8, pp 771-772, issn 0361-5960Article

Phase II study of carboplatin in patients with ovarian carcinoma: a national cancer institute of Canada clinical trials group studyEISENHAUER, E. A; SWENERTON, K. D; STURGEON, J. F. G et al.Cancer treatment reports. 1986, Vol 70, Num 10, pp 1195-1198, issn 0361-5960Article

New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1)EISENHAUER, E. A; THERASSE, P; RUBINSTEIN, L et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 228-247, issn 0959-8049, 20 p.Article

Evaluation of lymph nodes with RECIST 1.1SCHWARTZ, L. H; BOGAERTS, J; FORD, R et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 261-267, issn 0959-8049, 7 p.Article

New guidelines to evaluate the response to treatment in solid tumorsTHERASSE, P; ARBUCK, S. G; GWYTHER, S. G et al.Journal of the National Cancer Institute. 2000, Vol 92, Num 3, pp 205-216, issn 0027-8874Article